Lexeo Therapeutics, Inc. - Common Stock (LXEO)

CUSIP: 52886X107

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class
Equity / Common Stock
Shares outstanding
74,300,257
Total 13F shares
26,566,622
Share change
+3,439,176
Total reported value
$426,105,401
Price per share
$16.04
Number of holders
57
Value change
+$55,254,655
Number of buys
37
Number of sells
21

Sponsored

Quarterly Holders Quick Answers

What is CUSIP 52886X107?
CUSIP 52886X107 identifies LXEO - Lexeo Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of LXEO - Lexeo Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
EVENTIDE ASSET MANAGEMENT, LLC
13F
Company
4.5%
3,369,147
$52,828,225 31 Mar 2024
13F
JANUS HENDERSON GROUP PLC
13F
Company
3.4%
2,540,785
$39,802,357 31 Mar 2024
13F
D1 Capital Partners L.P.
13F
Company
3.4%
2,506,607
$39,303,598 31 Mar 2024
13F
CITADEL ADVISORS LLC
13F
Company
3.4%
2,502,981
$38,884,020 31 Mar 2024
13F
Omega Fund Management, LLC
13F
Company
3.2%
2,355,904
$36,940,575 31 Mar 2024
13F
Longitude Capital Partners IV, LLC
3/4/5
10%+ Owner
class O/S missing
2,567,100
$33,933,468 07 Nov 2023
Omega Fund VI, L.P.
3/4/5
10%+ Owner
class O/S missing
2,157,623
$28,520,755 07 Nov 2023
Novo Holdings A/S
13F
Company
2.2%
1,638,298
$25,688,513 31 Mar 2024
13F
Invest A/s Lundbeckfond
3/4/5
10%+ Owner
class O/S missing
1,835,959
$24,268,808 07 Nov 2023
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F
Company
1.8%
1,322,736
$20,740,500 31 Mar 2024
13F
BRAIDWELL LP
13F
Company
1.8%
1,322,277
$20,733,303 31 Mar 2024
13F
Artal Group S.A.
13F
Company
1.1%
801,716
$12,570,907 31 Mar 2024
13F
Blackstone Inc.
13F
Company
0.94%
696,110
$10,915,005 31 Mar 2024
13F
BlackRock Finance, Inc.
13F
Company
0.89%
662,962
$10,395,243 31 Mar 2024
13F
RA CAPITAL MANAGEMENT, L.P.
13F
Company
0.89%
660,938
$10,363,508 31 Mar 2024
13F
MILLENNIUM MANAGEMENT LLC
13F
Company
0.8%
593,722
$8,725,853 31 Mar 2024
13F
VANGUARD GROUP INC
13F
Company
0.65%
481,755
$7,553,919 31 Mar 2024
13F
Laurion Capital Management LP
13F
Company
0.61%
454,182
$7,121,574 31 Mar 2024
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.27%
197,799
$3,101,960 31 Mar 2024
13F
Vestal Point Capital, LP
13F
Company
0.24%
175,000
$2,744,000 31 Mar 2024
13F
CORNELL UNIVERSITY
13F
Company
0.17%
126,258
$1,979,725 31 Mar 2024
13F
STATE STREET CORP
13F
Company
0.15%
112,215
$1,759,531 31 Mar 2024
13F
BANK OF MONTREAL /CAN/
13F
Company
0.15%
111,186
$1,751,180 31 Mar 2024
13F
NORTHERN TRUST CORP
13F
Company
0.11%
82,101
$1,287,344 31 Mar 2024
13F
Verition Fund Management LLC
13F
Company
0.08%
60,843
$954,018 31 Mar 2024
13F
CITIGROUP INC
13F
Company
0.07%
49,177
$771,095 31 Mar 2024
13F
JANE STREET GROUP, LLC
13F
Company
0.05%
39,933
$626,149 31 Mar 2024
13F
Bank of New York Mellon Corp
13F
Company
0.04%
28,323
$444,105 31 Mar 2024
13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
13F
Company
0.04%
27,361
$429,020 31 Mar 2024
13F
GOLDMAN SACHS GROUP INC
13F
Company
0.03%
23,559
$369,405 31 Mar 2024
13F
BARCLAYS PLC
13F
Company
0.03%
22,929
$359,527 31 Mar 2024
13F
Jump Financial, LLC
13F
Company
0.02%
14,894
$233,538 31 Mar 2024
13F
Paul McCormac
3/4/5
Chief Technical Officer
class O/S missing
17,349
$229,329 07 Nov 2023
RENAISSANCE TECHNOLOGIES LLC
13F
Company
0.02%
14,576
$229,000 31 Mar 2024
13F
MORGAN STANLEY
13F
Company
0.02%
13,944
$218,642 31 Mar 2024
13F
Nuveen Asset Management, LLC
13F
Company
0.02%
13,478
$211,335 31 Mar 2024
13F
Woodline Partners LP
13F
Company
0.02%
12,051
$188,960 31 Mar 2024
13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
0.02%
12,041
$188,803 31 Mar 2024
13F
UBS Group AG
13F
Company
0.01%
10,367
$162,555 31 Mar 2024
13F
CAXTON CORP
13F
Company
0.01%
10,319
$161,796 31 Mar 2024
13F
RHUMBLINE ADVISERS
13F
Company
0.01%
9,730
$152,561 31 Mar 2024
13F
JPMORGAN CHASE & CO
13F
Company
0.01%
5,953
$93,344 31 Mar 2024
13F
MetLife Investment Management, LLC
13F
Company
0.01%
5,821
$91,273 31 Mar 2024
13F
BANK OF AMERICA CORP /DE/
13F
Company
0.01%
5,271
$82,649 31 Mar 2024
13F
AMERICAN INTERNATIONAL GROUP, INC.
13F
Company
0.01%
5,053
$79,231 31 Mar 2024
13F
BNP PARIBAS FINANCIAL MARKETS
13F
Company
0.01%
4,781
$74,966 31 Mar 2024
13F
NEW YORK STATE COMMON RETIREMENT FUND
13F
Company
0.01%
4,100
$64,288 31 Mar 2024
13F
WELLS FARGO & COMPANY/MN
13F
Company
0%
3,369
$52,826 31 Mar 2024
13F
STRS OHIO
13F
Company
0%
1,800
$28,000 31 Mar 2024
13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
13F
Company
0%
1,031
$16,166 31 Mar 2024
13F

Institutional Holders of Lexeo Therapeutics, Inc. - Common Stock (LXEO) as of Q2 2024

As of 30 Jun 2024, Lexeo Therapeutics, Inc. - Common Stock (LXEO) was held by 57 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 26,566,622 shares. The largest 10 holders included EVENTIDE ASSET MANAGEMENT, LLC, JANUS HENDERSON GROUP PLC, ADAGE CAPITAL PARTNERS GP, L.L.C., CITADEL ADVISORS LLC, D1 Capital Partners L.P., Omega Fund Management, LLC, Novo Holdings A/S, BRAIDWELL LP, Vestal Point Capital, LP, and Woodline Partners LP. This page lists 57 institutional shareholders reporting positions in this security for the Q2 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders
54
Q2 2024 holders
57
Holder diff
3
Investor Q1 2024 Shares Q2 2024 Shares Share Diff Share Chg % Q1 2024 Value $ Q2 2024 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.